physostigmine has been researched along with Acute Confusional Senile Dementia in 233 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 78 (33.48) | 18.7374 |
| 1990's | 78 (33.48) | 18.2507 |
| 2000's | 49 (21.03) | 29.6817 |
| 2010's | 23 (9.87) | 24.3611 |
| 2020's | 5 (2.15) | 2.80 |
| Authors | Studies |
|---|---|
| Andrisano, V; Bolognesi, ML; Budriesi, R; Cavalli, A; Cavrini, V; Melchiorre, C; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Brufani, M; Cellai, L; Perola, E | 1 |
| Andrisano, V; Bartolini, M; Bidon-Chanal, A; de Austria, C; del Monte-Millán, M; Dorronsoro, I; García-Palomero, E; Luque, FJ; Martínez, A; Medina, M; Muñoz-Ruiz, P; Orozco, M; Rubio, L; Usán, P; Valenzuela, R | 1 |
| Decker, M; Lehmann, J; Rommelspacher, H; Schott, Y | 1 |
| Ashraf, M; Bajda, M; Hussain, S; Khan, IU; Mustafa, G; Mutahir, S; Rehman, TU; Riaz, S; Shaukat, A; Yar, M | 1 |
| Andrisano, V; Bartolini, M; Belluti, F; Bisi, A; Di Marzo, V; Gobbi, S; Ligresti, A; Montanari, S; Mor, M; Rampa, A; Rivara, S; Scalvini, L | 1 |
| Darekar, MN; Gurjar, AS; Ooi, L; Yeong, KY | 1 |
| Ji, J; Peng, Y; Rakesh, KP; Wang, S; Xu, M; Zhu, L | 1 |
| Cahlíková, L; Carmen Catapano, M; Hulcová, D; Janoušek, J; Jenčo, J; Kohelová, E; Korábečný, J; Kučera, T; Kuneš, J; Maafi, N; Maříková, J; Mecava, M; Nováková, L; Pidaný, F; Prchal, L; Schmidt, M; Shammari, LA; Špulák, M | 1 |
| Li, J; Liu, D; Liu, W; Shi, T; Wang, D; Wang, Y; Wang, Z; Yin, G; Zhang, H | 1 |
| Li, X; Wang, S; Wang, Y; Wang, Z; Zhang, H | 1 |
| Adeniyi, AA; Conradie, J | 1 |
| Chen, XQ; Kleschevnikov, AM; Maccecchini, M; Mobley, WC; Nguyen, PD; Overk, C; Pearn, ML; Salehi, A | 1 |
| David, B; Gohlke, H; Pietruszka, J; Schäfer, P; Schneider, P | 1 |
| Nuñez, A; Reyes-Marin, KE | 1 |
| Aarsland, D; Ballard, C; Becker, RE; Bledsoe, J; Ferrucci, L; Flanagan, D; Govindarajan, R; Greig, NH; Kapogiannis, D; Lahiri, DK; Majercik, S; Sano, M; Schneider, LS | 1 |
| Bader, M; Becker, RE; Greig, NH; Hoffer, BJ; Hoffman, AF; Hsueh, SC; Jung, YJ; Lecca, D; Lupica, CR; Pick, CG; Tweedie, D | 1 |
| Cesario, A; Del Bufalo, A; Fini, M; Frustaci, A; Russo, P | 1 |
| Gonzalez, D; Greig, NH; Lilja, AM; Marutle, A; Mustafiz, T; Nordberg, A; Röjdner, J; Storelli, E; Thomé, CM; Unger-Lithner, C | 1 |
| Balleidier, A; Bandyopadhyay, S; Cahill, C; Huang, C; Huang, X; Lahiri, DK; Rogers, JT | 1 |
| Darreh-Shori, T; Hosseini, SM; Nordberg, A | 1 |
| Lilja, AM; Malmsten, L; Marutle, A; Nordberg, A; Ögren, SO; Röjdner, J; Verkhratsky, A; Voytenko, L | 1 |
| Almkvist, O; Andreasen, N; Kadir, A; Långström, B; Nordberg, A; Wall, A; Zetterberg, H | 1 |
| Greig, NH; Kamal, MA; Nawaz, MS; Qu, X; Shakil, S; Tan, Y; Tweedie, D; Yu, QS | 1 |
| Calabrese, EJ | 1 |
| Agbedahunsi, JM; Ahmed, T; Choudhary, MI; Ghayur, MN; Gilani, AH; Houghton, PJ; Khalid, A; Nawaz, SA | 1 |
| Merchant, S; Sugaya, K | 1 |
| Lahiri, DK; Schneider, LS | 1 |
| Bentley, P; Dolan, RJ; Driver, J | 2 |
| Jehangir, B; Mahmood, U; Ul-Haq, Z | 1 |
| Becker, RE; Bruinsma, G; Friedhoff, LT; Frölich, L; Giacobini, E; Greig, NH; Winblad, B | 1 |
| Chiou, G; Garg, NK; Schammel, AW | 1 |
| Becker, RE; Greig, NH | 2 |
| Reale, M; Tata, AM | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Lahiri, DK; Luo, W; Ray, B; Reale, M; Rogers, JT; Sambamurti, K; Yu, QS | 1 |
| Batool, S; Greig, NH; Kamal, MA; Nawaz, MS; Rehan, M | 1 |
| Greig, NH; Li, Y; Lilja, AM; Luo, Y; Marini, AM; Marutle, A; Nordberg, A; Röjdner, J; Yu, QS | 1 |
| Houghton, PJ; Howes, MJ; Perry, NS | 1 |
| Butler, R; Prabhakaran, P; Warner, J | 1 |
| Rakonczay, Z | 1 |
| Chapin, D; Hubbard, ST; Jones, SB; Liston, DR; Nason, D; Nielsen, JA; Ramirez, A; Shalaby, IA; Villalobos, A; White, WF | 1 |
| Nagura, H | 1 |
| Hallam, KT; Horgan, JE; McGrath, C; Norman, TR | 1 |
| Arya, P; Butler, R; Warner, J | 2 |
| Bertchume, A; Csernansky, CA; Csernansky, JG; Dong, H; Martin, MV; Vallera, D | 1 |
| Brossi, A; Bruinsma, GB; Greig, NH; Lahiri, DK; Sambamurti, K; Yu, QS | 1 |
| Thatte, U | 1 |
| Frey, KA; Kilbourn, MR; Koeppe, RA; Kuhl, DE; Minoshima, S; Snyder, SE | 1 |
| Al-Jafari, AA; Greig, NH; Kamal, MA; Yu, QS | 1 |
| Castro, A; Martinez, A | 1 |
| Butler, R; Warner, J; Wuntakal, B | 1 |
| Brossi, A; Chen, D; Davidson, D; Giordano, T; Greig, NH; Holloway, HW; Lahiri, DK; Sambamurti, K; Utsuki, T; Yu, QS | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Klein, P; Li, Y; Tweedie, D; Yu, QS | 1 |
| Chen, D; Giordano, T; Greig, NH; Holloway, HW; Lahiri, DK; Maloney, B; Sambamurti, K; Utsuki, T; Yu, QS | 1 |
| Klein, J | 1 |
| Alley, GM; Chen, D; Greig, NH; Lahiri, DK; Tweedie, D | 1 |
| Greig, NH; Marutle, A; Nilbratt, M; Nordberg, A; Ohmitsu, M; Sugaya, K | 1 |
| Conner, CS; Rathmann, KL | 1 |
| Bajda, M; Malawska, B; Musiał, A | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Klein, P; Li, Y; Luo, W; Tweedie, D | 1 |
| Greig, NH; Holloway, HW; Kamal, MA; Li, Y; Qu, X; Tan, Y; Tweedie, D; Yu, QS | 1 |
| Akaike, A; Goto, Y; Hongo, H; Kihara, T; Niidome, T; Sugimoto, H | 1 |
| Almkvist, O; Andreasen, N; Blennow, K; Engler, H; Forsberg, A; Hagman, G; Kadir, A; Långström, B; Lärksäter, M; Nordberg, A; Wall, A; Winblad, B; Zetterberg, H | 1 |
| Jolles, J; Verhoeven, WM | 1 |
| Davies, P | 1 |
| Davis, KL; Greenwald, BS | 1 |
| Gershon, S; Goodnick, P | 1 |
| Fuld, PA; Masur, DM; Sharpless, NS; Thal, LJ | 1 |
| Brinkman, SD; Gershon, S | 1 |
| Jotkowitz, S | 1 |
| Davis, BM; Davis, KL; Greenwald, BS; Horvath, TB; Johns, CA; Levy, MI; Mohs, RC; Rosen, WG | 1 |
| Davies, P; Fuld, PA; Masur, DM; Sharpless, NS; Thal, LJ | 2 |
| Coco, A; Davis, KL; Deutsch, SI; Horvath, T; Levy, MI; Mohs, RC; Rothpearl, AB; Stockton, D | 1 |
| Levin, HS; Peters, BH | 2 |
| Ando, K; Muramoto, O; Sugishita, M | 1 |
| Davis, KL; Mohs, RC | 2 |
| Blass, JP; Weksler, ME | 1 |
| Wettstein, A | 1 |
| Albanese, A; Caltagirone, C; Gainotti, G; Masullo, C | 1 |
| Raber, P | 1 |
| Christie, JE; Ferguson, J; Glen, AI; Shering, A | 1 |
| Denber, HC | 1 |
| Davis, KL; Levy, MI; Mohs, RC; Rosen, WG | 1 |
| Caltagirone, C; Gainotti, G; Masullo, C | 1 |
| Ashford, JW; Cochran, L; Jarvik, LF; Schaeffer, J; Soldinger, S | 1 |
| Corkin, S; Growdon, JH | 1 |
| Asthana, S; Greig, NH; Hegedus, L; Holloway, HH; Raffaele, KC; Schapiro, MB; Soncrant, TT | 1 |
| Prohovnik, I; Wirkowski, E; Young, WL | 1 |
| Bowen, DM; Dijk, SN; Francis, PT; Stratmann, GC | 1 |
| Imbimbo, BP; Luzzana, M; Mosca, A; Onelli, E; Paleari, R; Rosti, E | 1 |
| Bragadin, M; Dell'Antone, P; Zatta, P | 1 |
| Bahro, M; Berger, M; Gann, H; Hohagen, F; Lis, S; Riemann, D; Stadmüller, G | 1 |
| Borroni, E; Da Prada, M; Damsma, G; Giovacchini, C; Jakob-Rötne, R; Mutel, V | 1 |
| Barchowsky, A; Block, GA; Cutler, NR; Reines, SA; Sawin, SF; Sramek, JJ | 1 |
| Brossi, A; Greig, NH; Ingram, DK; Pei, XF; Soncrant, TT | 1 |
| Håkansson, L | 1 |
| Blin, J; Chase, TN; Giuffra, ME; Mouradian, MM; Piercey, MF | 1 |
| Mohammed, AH | 1 |
| Johansson, M; Nordberg, A | 1 |
| Coull, JT; Sahakian, BJ | 1 |
| Gustafson, L | 1 |
| Whitehouse, PJ | 1 |
| Brandeis, R; Dachir, S; Feiler, D; Glikfeld, P; Grunwald, J; Levy, A; Mawassi, F; Meshulam, Y; Treves, TA; Wengier, A | 1 |
| Aisen, PS; Bierer, LM; Davidson, M; Davis, KL; Ryan, TM; Schmeidler, J; Stern, RG | 1 |
| Aronson, SM; Berent, S; Giordani, B; Mellow, AM | 1 |
| Olin, JT; Pawluczyk, S; Schneider, LS | 1 |
| Bell, K; Marder, K; Mayeux, R; Sano, M; Stern, Y; Stricks, L | 1 |
| Cummings, JL; Gorman, DG; Shapira, J | 1 |
| Cutler, NR; Sramek, JJ | 2 |
| Bodenheimer, S; Dorsa, DM; Pascualy, M; Peskind, ER; Raskind, MA; Thal, L; Veith, RC; Wingerson, D | 1 |
| Bierer, LM; Davis, KL; Jacobson, R; Lawlor, BA; Marin, DB; Mohs, RC; Ryan, TM; Schmeidler, J | 1 |
| Asthana, S; Berardi, A; Greig, NH; Haxby, JV; Raffaele, KC; Schapiro, MB; Soncrant, TT | 1 |
| Dobie, DJ; Pascualy, M; Peskind, ER; Raskind, MA; Thal, LJ; Wilkinson, CW; Wingerson, D | 1 |
| Canal, N; Imbimbo, BP | 1 |
| Ghezzi, A; Imbimbo, BP; Luzzana, M; Mosca, A; Paleari, R | 1 |
| Bodenheimer, S; Goldberg, A; Harrell, L; Knopman, D; Philpot, M; Rossor, M; Sano, M; Schor, J; Schwartz, G; Thal, LJ; Weiner, M | 1 |
| Mielke, R | 1 |
| Arnold, SE; Lucas, LR; Prohovnik, I; Smith, G | 1 |
| Acevedo, LD; Davis, KL; Gluck, R; Greig, N; Haroutunian, V; Pei, XF; Utsuki, T; Wallace, WC | 1 |
| Gold, M | 1 |
| Bokonjić, D; Dobrić, S; Jovanova-Nesić, K; Kostić, VS; Popović, M; Popović, N; Rosić, N | 1 |
| Cavalli, A; Hansch, C; Recanatini, M | 1 |
| Oakley, F; Sunderland, T | 1 |
| Brufani, M; Cellai, L; Filocamo, L; Lamba, D; Perola, E | 1 |
| Lichtman, SW; Seliger, G; Taverni, JP | 1 |
| Blin, J; Bol, A; De Volder, A; Duprez, T; Ivanoiu, A; Laterre, EC; Michel, C; Seron, X; Verellen, C | 1 |
| Alberoni, M; Imbimbo, BP; Lucca, U; Lucchelli, F; Thal, LJ | 1 |
| Calcagnini, G; Fieschi, C; Frontoni, M; Giubilei, F; Imbimbo, BP; Lino, S; Santini, M; Strano, S; Tisei, P | 1 |
| Scheltens, P; Verhey, FR | 1 |
| Imbimbo, BP; Lucca, U; Lucchelli, F; Martelli, P; Thal, LJ; Troetel, WM | 1 |
| Carlier, PR; Han, YF; Hui, KM; Li, CY; Li, ZW; Pang, YP; Wang, H; Xue, H | 1 |
| Ferguson, JM; Mintzer, J; Raskin, A; Targum, SD; Thal, LJ | 1 |
| Brossi, A; Greig, NH; Holloway, HW; Utsuki, T; Yu, Q | 1 |
| Hampel, H; Hegerl, U; Schmitt, W; Walter, K | 1 |
| Kaur, J; Zhang, MQ | 1 |
| Falk, WE; Mattes, JA; Newhouse, P; van Dyck, CH | 1 |
| Dukoff, R; Greenwood, PM; Levy, JA; Parasuraman, R; Sunderland, T | 1 |
| Al-Jafari, AA; Alhomida, AS; Greig, NH; Kamal, MA | 1 |
| Foster, NL; Frey, KA; Kilbourn, MR; Koeppe, RA; Kuhl, DE; Minoshima, S | 1 |
| Dobie, DJ; Peskind, ER; Petrie, EC; Raskind, MA; Veith, RC | 1 |
| Chen, CF; Chou, CJ; Liao, JF; Wang, HH | 1 |
| Kosasa, T; Kuriya, Y; Ogura, H; Yamanishi, Y | 1 |
| Brossi, A; De Micheli, E; Deutsch, J; Greig, NH; Holloway, HW; Ingram, DK; Lahiri, DK; Perry, TA; Soncrant, TT; Utsuki, T; Yu, QS | 1 |
| Birks, J; Coelho, F | 1 |
| Braida, D; Sala, M | 1 |
| Robert, P | 1 |
| Blount, PJ; McDeavitt, JT; Nguyen, CD | 1 |
| Smith, CM; Swash, M | 2 |
| Davis, KL; Hollister, LE; Kopell, BS; Mohs, RC; Pfefferbaum, A; Tinklenberg, JR | 1 |
| Muramoto, O; Sugishita, M; Sugita, H; Toyokura, Y | 1 |
| Lalonde, F; Lawlor, B; Martinez, R; Martinson, H; Mellow, A; Molchan, S; Putnam, K; Sunderland, T | 1 |
| Baĭmanov, TD; Burov, IuV; Maĭsov, NI | 1 |
| Giacobini, E; Ogane, N; Struble, R | 1 |
| Curran, SM; Dougal, NJ; Ebmeier, KP; Goodwin, GM; Hanson, MT; Hunter, R; Murray, CL; Patterson, J; Siegfried, K; Wyper, DJ | 1 |
| Besson, JA; Crawford, JR; Evans, NT; Gemmell, HG; Roeda, D | 1 |
| Stern, GM | 1 |
| Boddeke, H; Enz, A; Gray, J; Spiegel, R | 1 |
| Becker, RE; Hutt, V; Imbimbo, BP; Unni, LK | 1 |
| Minichiello, M; Molchan, SE; Sunderland, T; Vitiello, B | 1 |
| Burov, IuV; Kadysheva, LV; Robakidze, TN; Shaposhnikova, GI; Voronin, AE | 1 |
| Brandt, J; Burns, A; Folstein, MF; Frost, JJ; Harris, G; Mayberg, H; Sapp, J; Steele, C; Tune, L; Wagner, HN | 1 |
| Davis, KL; Haroutunian, V; Santucci, AC | 2 |
| Miyoshi, K; Ueki, A | 1 |
| Cowen, PJ; Geaney, DP; Shepstone, BJ; Soper, N | 1 |
| Goodwin, GM; Hansen, MT; Hunter, R; Patterson, J; Wyper, DJ | 1 |
| Bowen, D; Francis, P; Tyrrell, P; Wilson, K | 1 |
| Volger, BW | 1 |
| Guterman, A; Sevush, S; Villalon, AV | 1 |
| Brufani, M; Giacobini, E; Pomponi, M | 1 |
| Bhat, RV; Collins, AC; Marks, MJ; Turner, SL | 1 |
| Albert, MS; Baer, L; Jenike, MA | 1 |
| Callaway, R; Falgout, J; Harrell, LE; Morere, D | 1 |
| Geula, C; Mesulam, MM | 1 |
| Albert, MS; Goff, D; Gunther, J; Heller, H; Jenike, MA | 1 |
| Avery, C; Callaway, R; Falgout, J; Halsey, JH; Harrell, LE; Jope, RS; Leli, D; Morere, D; Spiers, M | 1 |
| Drukarch, B; Kits, KS; Lodder, JC; Stoof, JC; Van der Meer, EG | 1 |
| Borson, S; Dorsa, DM; Gumbrecht, G; Lampe, TH; Peskind, ER; Raskind, MA; Risse, SC; Veith, RC | 1 |
| Beckmann, H; Heinsen, H; Maurer, K; Riederer, P | 1 |
| Blau, AD; Fuld, PA; Klauber, MR; Masur, DM; Thal, LJ | 1 |
| Bierer, LM; Davidson, M; Davis, KL; Kaminsky, R; Ryan, TM | 1 |
| Chen, AD; Connor, DJ; Mandel, RJ; Thal, LJ | 1 |
| Davis, BM; Davis, KL; Greenwald, BS; Horvath, TB; Johns, CA; Mathé, AA; Mohs, RC | 2 |
| Campbell, GA; Davis, KL; Haroutunian, V; Kanof, PD; Tsuboyama, GK | 1 |
| Amaducci, L; Lippi, A | 1 |
| Bobotas, G; Lasker, B; Nigalye, A; Schor, JM; Sharpless, NS; Thal, LJ | 1 |
| Becker, RE; Giacobini, E; Hannant, ME; Unni, LK | 1 |
| Davis, KL; Hollander, E; Mohs, RC | 1 |
| Moulthrop, MA; Rose, RP | 1 |
| Hinzen, DH | 1 |
| Ohtomo, E | 1 |
| Becker, R; Elble, R; Giacobini, E; McIlhany, M; Sherman, K | 1 |
| Beller, SA; Overall, JE; Rhoades, HM; Swann, AC | 1 |
| Mayeux, R; Sano, M; Stern, Y | 2 |
| Ashford, W; Colliver, J; Giacobini, E; Kumar, V; Murphy, J; Sherman, KA; Smith, RC | 1 |
| Jarema, M | 1 |
| Coogan, JS; Hart, S; Smith, CM | 1 |
| Dahlgren, N; Edvinsson, L; Fernö, H; Gustafson, L; Hagberg, B; Risberg, J; Rosén, I | 1 |
| Iga, Y; Kawanishi, G; Mizobe, F; Nakahara, N | 1 |
| Brufani, M; Castellano, C; Marta, M; Oliverio, A; Pagella, PG; Pavone, F; Pomponi, M | 1 |
| Barrett, G; Neshige, R; Shibasaki, H | 1 |
| Joyce, E; Lishman, WA; Sahakian, B | 1 |
| Read, SL | 1 |
| Abramowitz, C; Davous, P; Lamour, Y; Piketty, ML; Roudier, M | 1 |
| Friedman, D | 1 |
| Geula, C; Mesulam, MM; Morán, MA | 1 |
| Kohlstaedt, EV; Schwartz, AS | 1 |
| Adem, A; Hardy, J; Nilsson, L; Nordberg, A; Winblad, B | 1 |
| Blackwood, DH; Christie, JE | 1 |
| Brufani, M; Marta, M; Pomponi, M | 1 |
| Cain, JW | 1 |
| Davidson, M; Davis, BM; Davis, KL; Hollander, E; Horvath, TB; Mohs, RC; Ryan, T | 1 |
| Hardy, J; Nilsson, L; Nordberg, A; Wester, P; Winblad, B | 1 |
| Albert, M; Jenike, M; Mayeux, R | 1 |
| Beller, SA; Overall, JE; Swann, AC | 1 |
| Huey, LY; Janowsky, DS; Kennedy, B; Risch, SC; Ziegler, M | 1 |
| Davis, KL; Haroutunian, V; Kanof, P | 1 |
| Dysken, MW; Janowsky, DS | 1 |
| Hart, SA; Smith, CM; Swash, M | 1 |
42 review(s) available for physostigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship; Triazoles | 2019 |
Recent advance on carbamate-based cholinesterase inhibitors as potential multifunctional agents against Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Ligands | 2022 |
(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Cell Death; Cholinesterase Inhibitors; Humans; Physostigmine | 2018 |
Multitarget drugs of plants origin acting on Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Biological Products; Cholinesterase Inhibitors; Crocus; Drug Discovery; Galantamine; Galanthus; Ginkgo biloba; Humans; Huperzia; Neuroprotective Agents; Physostigmine; Plant Extracts; Plants; Salvia; Sesquiterpenes | 2013 |
Alzheimer's disease drugs: an application of the hormetic dose-response model.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Nootropic Agents; Physostigmine | 2008 |
How to approach Alzheimer's disease therapy using stem cell technologies.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cell Differentiation; Cell Proliferation; Cholinesterase Inhibitors; Cognition; Humans; Mice; Neurons; Physostigmine; Rats; Stem Cell Transplantation; Stem Cells | 2008 |
Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders.
Topics: Alkaloids; Alzheimer Disease; Estrogens, Non-Steroidal; Galantamine; Humans; Isoflavones; Physostigmine; Phytoestrogens; Phytotherapy; Plant Extracts; Plant Preparations; Plants, Medicinal; Sesquiterpenes | 2003 |
Dementia.
Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phosphatidylcholines; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine; Vitamin E | 2003 |
[Drugs for the treatment of Alzheimer's disease].
Topics: Acetylcholine; Alzheimer Disease; Antidepressive Agents; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Haloperidol; Humans; Hydroxyzine; Hypnotics and Sedatives; Indans; Injections, Intramuscular; Physostigmine; Piperidines; Selective Serotonin Reuptake Inhibitors; Tacrine | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine | 2004 |
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Physostigmine; Tartrates | 2005 |
Phenserine Axonyx.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Molecular Structure; Physostigmine | 2005 |
Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Galantamine; Humans; Physostigmine; Protein Conformation | 2006 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine | 2005 |
Phenserine.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase II as Topic; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Investigational; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Mice; Physostigmine; Risk Assessment; Sensitivity and Specificity; Treatment Outcome | 2007 |
Alzheimer's disease: clinical features, pathogenesis, and treatment. 1984.
Topics: Alzheimer Disease; Animals; Cholinergic Agents; Cholinesterase Inhibitors; History, 20th Century; Humans; Naloxone; Narcotic Antagonists; Physostigmine | 2007 |
Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Topics: Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Indole Alkaloids; Isoquinolines; Phenylcarbamates; Physostigmine; Piperidines; Propidium; Rivastigmine; Steroids; Tacrine | 2007 |
[Psychopharmacologic treatment of cognitive function disorders in aging persons: current possibilities].
Topics: Adrenocorticotropic Hormone; Aged; Alzheimer Disease; Anticonvulsants; Brain; Catecholamines; Choline; Dementia; Dihydroergotoxine; Humans; Memory Disorders; Narcotic Antagonists; Nerve Tissue Proteins; Neuropsychology; Parasympatholytics; Phosphatidylcholines; Physostigmine; Piracetam; Trace Elements; Vasopressins; Vitamins | 1984 |
An update on the neurochemistry of Alzheimer disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Arecoline; Brain; Choline; Choline O-Acetyltransferase; Cholinergic Fibers; Dementia; Dopamine; gamma-Aminobutyric Acid; Humans; Neurotransmitter Agents; Norepinephrine; Peptides; Phosphatidylcholines; Physostigmine; Serotonin | 1983 |
Experimental pharmacology of Alzheimer disease.
Topics: Acetylcholine; Adult; Aged; Alzheimer Disease; Dementia; Dopamine; gamma-Aminobutyric Acid; Humans; Middle Aged; Norepinephrine; Oxotremorine; Peptides; Physostigmine; Receptors, Cholinergic; Serotonin; Somatostatin; Synaptic Transmission | 1983 |
Chemotherapy of cognitive disorders in geriatric subjects.
Topics: Adrenocorticotropic Hormone; Aged; Aging; Alzheimer Disease; Arecoline; Brain Chemistry; Choline; Cognition Disorders; Cyclandelate; Electroencephalography; Humans; Memory; Methylphenidate; Pentylenetetrazole; Phosphatidylcholines; Physostigmine; Piracetam; Procaine; Vasodilator Agents; Vasopressins | 1984 |
Measurement of cholinergic drug effects on memory in Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Memory; Memory Disorders; Parasympatholytics; Parasympathomimetics; Physostigmine; Scopolamine; Tacrine | 1983 |
Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Physostigmine; Rats; Structure-Activity Relationship | 1995 |
Mechanism of action of cholinesterase inhibitors in Alzheimer's disease.
Topics: Acetylcholine; Aged; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Female; Humans; Male; Neurotransmitter Agents; Physostigmine; Receptors, Cholinergic; Tacrine | 1993 |
Pharmacokinetic studies of cholinesterase inhibitors.
Topics: Adult; Aged; Alzheimer Disease; Female; Galantamine; Humans; Male; Middle Aged; Physostigmine; Tacrine | 1993 |
Cholinergic therapy in dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Physostigmine; Receptors, Muscarinic; Receptors, Nicotinic; Tacrine | 1993 |
Molecular modelling and QSAR of reversible acetylcholines-terase inhibitors.
Topics: Alkaloids; Alzheimer Disease; Cholinesterase Inhibitors; Crystallography, X-Ray; Donepezil; Drug Design; Glaucoma; Humans; Indans; Models, Molecular; Myasthenia Gravis; Neostigmine; Physostigmine; Piperidines; Sesquiterpenes; Structure-Activity Relationship; Surface Properties; Tacrine | 2000 |
Physostigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Physostigmine; Randomized Controlled Trials as Topic | 2001 |
Eptastigmine: ten years of pharmacology, toxicology, pharmacokinetic, and clinical studies.
Topics: Acetylcholine; Acetylcholinesterase; Activities of Daily Living; Agranulocytosis; Alzheimer Disease; Animals; Behavior, Animal; Biogenic Monoamines; Brain; Cholinesterase Inhibitors; Cognition Disorders; Erythrocytes; Humans; Learning; Memory; Physostigmine; Randomized Controlled Trials as Topic | 2001 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2002 |
Clinical use of cholinomimetic agents: a review.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Brain Injuries; Carbamates; Clinical Trials as Topic; Cytidine Diphosphate Choline; Donepezil; Female; Follow-Up Studies; Humans; Indans; Injections, Intravenous; Injury Severity Score; Male; Middle Aged; Parasympathomimetics; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
New drug interventions in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Arginine Vasopressin; Cholinesterase Inhibitors; G(M1) Ganglioside; Humans; Mental Recall; Neuropsychological Tests; Physostigmine; Pilot Projects; Receptors, Cholinergic; Tacrine | 1992 |
Alternatives in the treatment of memory loss in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Memory Disorders; Multicenter Studies as Topic; Phosphatidylcholines; Physostigmine; Tacrine | 1991 |
Present state and future development of the therapy of Alzheimer disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Humans; Nerve Growth Factors; Neuropeptides; Parasympathomimetics; Physostigmine | 1990 |
Shifting patterns of cortical cholinesterases in Alzheimer's disease: implications for treatment, diagnosis, and pathogenesis.
Topics: Acetylcholinesterase; Alzheimer Disease; Cerebral Cortex; Humans; Physostigmine; Tacrine | 1990 |
Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Alzheimer Disease; Double-Blind Method; Humans; Memory; Physostigmine; Psychological Tests | 1989 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Humans; Parasympathomimetics; Physostigmine; Piracetam; Pyrrolidines; Research Design; Succinimides; Synapses | 1986 |
[Recent drug therapy of senile dementia].
Topics: Adrenocorticotropic Hormone; Alzheimer Disease; Choline; Dementia; Dihydroergotoxine; Humans; Narcotic Antagonists; Peptide Fragments; Phosphatidylcholines; Physostigmine; Piracetam; Pyrrolidines; Succinimides | 1987 |
Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain; Butyrylcholinesterase; Cholinergic Fibers; Cholinesterases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Injections, Intravenous; Injections, Intraventricular; Memory; Physostigmine | 1988 |
[Progress in the studies of the etiology and treatment of Alzheimer's disease].
Topics: Acetylcholine; Alzheimer Disease; Brain; Chromosome Aberrations; Chromosomes, Human, 21-22 and Y; Dopamine; gamma-Aminobutyric Acid; Humans; Physostigmine; Tacrine | 1988 |
Update on cholinergic enhancement therapy for Alzheimer disease.
Topics: Alzheimer Disease; Aminoacridines; Cholinergic Fibers; Cholinesterase Inhibitors; Humans; Physostigmine; Tacrine | 1987 |
65 trial(s) available for physostigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzothiazoles; Blotting, Western; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Drug Therapy, Combination; Fluorescence; Follow-Up Studies; Humans; Indans; Physostigmine; Piperidines; Thiazoles; Time Factors | 2014 |
Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Biomarkers; Brain; Cognition; Double-Blind Method; Female; Glucose; Humans; Male; Nootropic Agents; Peptide Fragments; Phosphorylation; Physostigmine; Positron-Emission Tomography; tau Proteins; Time Factors; Treatment Outcome | 2015 |
Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory.
Topics: Aged; Alzheimer Disease; Attention; Brain Mapping; Cholinesterase Inhibitors; Double-Blind Method; Face; Female; Humans; Magnetic Resonance Imaging; Male; Memory; Memory Disorders; Middle Aged; Neural Pathways; Pattern Recognition, Visual; Photic Stimulation; Physostigmine; Reaction Time; Temporal Lobe | 2009 |
Phenserine efficacy in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Physostigmine; Treatment Outcome | 2010 |
Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.
Topics: Aged; Alzheimer Disease; Attention; Brain; Brain Mapping; Cholinesterase Inhibitors; Double-Blind Method; Face; Female; Humans; Judgment; Magnetic Resonance Imaging; Male; Middle Aged; Pattern Recognition, Visual; Photic Stimulation; Physostigmine; Reaction Time | 2008 |
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid; Brain; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Physostigmine; Placebo Effect; Positron-Emission Tomography; Treatment Outcome | 2008 |
Memory enhancement with oral physostigmine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dementia; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Phosphatidylcholines; Physostigmine | 1983 |
Oral physostigmine and lecithin improve memory in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dementia; Double-Blind Method; Drug Therapy, Combination; Humans; Memory Disorders; Middle Aged; Phosphatidylcholines; Physostigmine | 1983 |
Measurement of cholinergic drug effects on memory in Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans; Memory; Memory Disorders; Parasympatholytics; Parasympathomimetics; Physostigmine; Scopolamine; Tacrine | 1983 |
Lack of clinical efficacy of chronic oral physostigmine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Female; Humans; Male; Physostigmine | 1983 |
A signal detectability analysis of the effect of physostigmine on memory in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dementia; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Physostigmine; Psychological Tests | 1982 |
Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Memory; Memory Disorders; Middle Aged; Physostigmine; Random Allocation | 1982 |
Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Dementia; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Memory; Middle Aged; Physostigmine | 1981 |
Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Individuality; Infusions, Intravenous; Male; Middle Aged; Physostigmine | 1995 |
A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment.
Topics: Acetylcholinesterase; Adolescent; Adult; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Drug Monitoring; Female; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Physostigmine; Reproducibility of Results | 1995 |
Cholinergic neurotransmission, REM sleep and depression.
Topics: Adolescent; Adult; Aged; Alzheimer Disease; Brain Stem; Cholinergic Agonists; Cholinergic Fibers; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Galantamine; Humans; Male; Mental Disorders; Middle Aged; Parasympathomimetics; Physostigmine; Polysomnography; Reaction Time; Receptors, Muscarinic; Sleep Stages; Sleep Wake Disorders; Sleep, REM; Succinimides; Synaptic Transmission; Tacrine | 1994 |
A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erythrocytes; Female; Humans; Male; Middle Aged; Physostigmine; Placebos | 1995 |
Metabolic effects of scopolamine and physostigmine in human brain measured by positron emission tomography.
Topics: Aged; Alzheimer Disease; Brain; Deoxyglucose; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Middle Aged; Neuropsychological Tests; Organ Specificity; Physostigmine; Reference Values; Scopolamine; Tomography, Emission-Computed | 1994 |
Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB.
Topics: Activities of Daily Living; Alzheimer Disease; Attention; Cross-Sectional Studies; Double-Blind Method; Drug Therapy, Computer-Assisted; Female; Humans; Male; Memory; Neuropsychological Tests; Nicotine; Physostigmine; Placebos; Reaction Time; Tacrine; Treatment Outcome | 1993 |
Physostigmine and tetrahydroaminoacridine treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cerebrovascular Circulation; Cross-Sectional Studies; Double-Blind Method; Electroencephalography; Female; Humans; Male; Neuropsychological Tests; Physostigmine; Tacrine; Treatment Outcome | 1993 |
Transdermal physostigmine in the treatment of Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Mental Status Schedule; Neuropsychological Tests; Physostigmine; Treatment Outcome | 1994 |
A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Blood Pressure; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Rate; Humans; Male; Middle Aged; Neuropsychological Tests; Physostigmine; Pilot Projects; Yohimbine | 1993 |
A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Delayed-Action Preparations; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Physostigmine; Pilot Projects; Psychiatric Status Rating Scales; Selegiline; Tacrine | 1993 |
Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Analysis of Variance; Double-Blind Method; Electrocardiography; Humans; Mental Recall; Middle Aged; Physostigmine; Prognosis; Psychiatric Status Rating Scales | 1993 |
Physostigmine ameliorates the delusions of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Delusions; Hallucinations; Humans; Male; Physostigmine; Receptors, Cholinergic | 1993 |
The target population in phase I clinical trials of cholinergic compounds in Alzheimer disease: the role of the "bridging study".
Topics: Alzheimer Disease; Cholinergic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Tolerance; Humans; Physostigmine; Safety; Tacrine | 1995 |
L-deprenyl and physostigmine for the treatment of Alzheimer's disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Mental Recall; Middle Aged; Monoamine Oxidase Inhibitors; Neuropsychological Tests; Physostigmine; Retention, Psychology; Selegiline; Treatment Outcome; Verbal Learning | 1995 |
Treatment of Alzheimer disease by continuous intravenous infusion of physostigmine.
Topics: Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Infusions, Intravenous; Male; Memory; Middle Aged; Physostigmine; Treatment Outcome | 1995 |
Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease. Eptastigmine Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Drug Administration Schedule; Erythrocytes; Female; Humans; Male; Middle Aged; Physostigmine | 1996 |
A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Physostigmine Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Physostigmine | 1996 |
Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Motor Skills; Neuropsychological Tests; Nootropic Agents; Physostigmine; Pilot Projects; Problem Solving; Psychometrics; Reproducibility of Results; Selegiline; Treatment Outcome | 1997 |
Physostigmine results in an increased decrement in brain glucose consumption in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Attention; Brain Chemistry; Cholinesterase Inhibitors; Female; Glucose; Humans; Male; Memory; Physostigmine; Reaction Time; Sympathetic Nervous System; Synaptic Transmission; Tomography, Emission-Computed | 1998 |
A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Physostigmine; Treatment Outcome | 1998 |
Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Physostigmine; Treatment Outcome | 1999 |
A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged; Physostigmine; Time Factors | 1999 |
Double-blind, randomized, placebo-controlled clinical trial on the efficacy and tolerability of a physostigmine patch in patients with senile dementia of the Alzheimer type.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Physostigmine; Time Factors; Treatment Outcome | 1999 |
Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neuropsychological Tests; Physostigmine; Placebos; Treatment Outcome; Vomiting | 2000 |
Physostigmine in Alzheimer's disease.
Topics: Adult; Alzheimer Disease; Clinical Trials as Topic; Dementia; Drug Evaluation; Humans; Injections, Subcutaneous; Intelligence Tests; Male; Memory; Memory Disorders; Neuropsychological Tests; Physostigmine; Placebos; Research Design | 1979 |
Physostigmine: improvement of long-term memory processes in normal humans.
Topics: Acetylcholine; Adolescent; Adult; Alzheimer Disease; Clinical Trials as Topic; Humans; Male; Memory; Memory, Short-Term; Physostigmine | 1978 |
Effect of physostigmine on constructional and memory tasks in Alzheimer's disease.
Topics: Alzheimer Disease; Dementia; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Physostigmine; Receptors, Cholinergic | 1979 |
Effects of physostigmine and lecithin on memory in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Dementia; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Phosphatidylcholines; Physostigmine | 1979 |
A strategy of "combination chemotherapy" in Alzheimer's disease: rationale and preliminary results with physostigmine plus deprenyl.
Topics: Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Neuropsychological Tests; Physostigmine; Selegiline | 1992 |
Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Physostigmine; Tacrine; Tomography, Emission-Computed, Single-Photon | 1992 |
Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Humans; Male; Phenylcarbamates; Physostigmine; Placebos; Rats; Rivastigmine | 1991 |
Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography.
Topics: Aged; Alzheimer Disease; Amphetamines; Blood Glucose; Brain; Cerebrovascular Circulation; Deoxyglucose; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neuropsychological Tests; Physostigmine; Pilot Projects; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1991 |
Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography.
Topics: Aged; Alzheimer Disease; Arousal; Attention; Blood Flow Velocity; Brain; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Physostigmine; Regional Blood Flow; Single-Blind Method; Tomography, Emission-Computed, Single-Photon | 1991 |
Alternatives in the treatment of memory loss in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Humans; Memory Disorders; Multicenter Studies as Topic; Phosphatidylcholines; Physostigmine; Tacrine | 1991 |
Improved verbal learning after outpatient oral physostigmine therapy in patients with dementia of the Alzheimer type.
Topics: Administration, Oral; Aged; Alzheimer Disease; Ambulatory Care; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Physostigmine; Placebos; Verbal Learning | 1991 |
Oral physostigmine as treatment for dementia of the Alzheimer type: a long-term outpatient trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Physostigmine; Placebos; Psychiatric Status Rating Scales | 1990 |
Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
Topics: Administration, Oral; Age Factors; Aged; Alzheimer Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Physostigmine; Placebos; Psychiatric Status Rating Scales | 1990 |
Biological and neuropsychological characterization of physostigmine responders and nonresponders in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Choline; Clinical Trials as Topic; Double-Blind Method; Erythrocytes; Female; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Physostigmine | 1990 |
Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Alzheimer Disease; Double-Blind Method; Humans; Memory; Physostigmine; Psychological Tests | 1989 |
Combined administration of physostigmine and clonidine to patients with dementia of the Alzheimer type: a pilot safety study.
Topics: Aged; Alzheimer Disease; Blood Pressure; Clinical Trials as Topic; Clonidine; Female; Heart Rate; Humans; Male; Physostigmine | 1989 |
Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies.
Topics: Administration, Oral; Aged; Alzheimer Disease; Analysis of Variance; Clinical Trials as Topic; Dexamethasone; Drug Evaluation; Female; Humans; Hydrocortisone; Infusions, Parenteral; Male; Memory; Middle Aged; Neuropsychological Tests; Physostigmine; Radioimmunoassay; Random Allocation; Somatostatin | 1985 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Humans; Parasympathomimetics; Physostigmine; Piracetam; Pyrrolidines; Research Design; Succinimides; Synapses | 1986 |
Potential pharmacotherapy of Alzheimer disease. A comparison of various forms of physostigmine administration.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain; Butyrylcholinesterase; Cholinergic Fibers; Cholinesterases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Injections, Intravenous; Injections, Intraventricular; Memory; Physostigmine | 1988 |
Long-term outpatient treatment of senile dementia with oral physostigmine.
Topics: Administration, Oral; Aged; Alzheimer Disease; Ambulatory Care; Clinical Trials as Topic; Female; Humans; Male; Memory Disorders; Middle Aged; Physostigmine; Psychological Tests; Research Design | 1988 |
Long-term administration of oral physostigmine in Alzheimer's disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Clinical Trials as Topic; Humans; Memory; Middle Aged; Neuropsychological Tests; Physostigmine; Time Factors | 1988 |
Cortisol responses to cholinergic drugs in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterases; Clinical Trials as Topic; Cognition; Double-Blind Method; Female; Humans; Hydrocortisone; Male; Middle Aged; Neostigmine; Physostigmine; Scopolamine | 1988 |
Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG.
Topics: Aged; Alzheimer Disease; Brain; Clinical Trials as Topic; Double-Blind Method; Electroencephalography; Evoked Potentials; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neuropsychological Tests; Physostigmine; Psychometrics; Regional Blood Flow | 1987 |
Cholinergic effects on constructional abilities and on mnemonic processes: a case report.
Topics: Alzheimer Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Memory; Mental Recall; Middle Aged; Phosphatidylcholines; Physostigmine; Psychological Tests; Psychomotor Performance; Retention, Psychology | 1987 |
Physostigmine effects in Alzheimer's disease: relationship to dementia severity.
Topics: Aged; Alzheimer Disease; Behavior; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Physostigmine | 1986 |
Effects of oral physostigmine in Alzheimer's disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Middle Aged; Neuropsychological Tests; Physostigmine | 1987 |
Oral physostigmine treatment of patients with Alzheimer's disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Hydrocortisone; Male; Middle Aged; Parasympathetic Nervous System; Physostigmine; Psychiatric Status Rating Scales; Psychological Tests; Sleep | 1985 |
Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level.
Topics: Administration, Oral; Aged; Alzheimer Disease; Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memory; Memory, Short-Term; Middle Aged; Physostigmine; Random Allocation | 1985 |
131 other study(ies) available for physostigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Erythrocytes; Humans; Kinetics; Ligands; Models, Molecular; Polyamines; Receptor, Muscarinic M2; Receptors, Muscarinic; Structure-Activity Relationship | 1998 |
Synthesis and activity studies of N-[omega-N'-(adamant-1'-yl)aminoalkyl]- 2-(4'-dimethylaminophenyl)acetamides: in the search of selective inhibitors for the different molecular forms of acetylcholinesterase.
Topics: Acetamides; Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Catalytic Domain; Cattle; Cholinesterase Inhibitors; Erythrocytes; Humans; Protein Conformation; Solubility; Structure-Activity Relationship; Torpedo | 1998 |
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cell Line, Tumor; Cholinesterase Inhibitors; Dimerization; Drug Design; Erythrocytes; Fluorometry; Humans; Models, Molecular; Nootropic Agents; Protein Binding; Structure-Activity Relationship; Tacrine | 2005 |
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Galantamine; Humans; Inhibitory Concentration 50; Phenylcarbamates; Physostigmine; Rivastigmine; Serotonin | 2006 |
Pyridine sulfonamide as a small key organic molecule for the potential treatment of type-II diabetes mellitus and Alzheimer's disease: In vitro studies against yeast α-glucosidase, acetylcholinesterase and butyrylcholinesterase.
Topics: Acetylcholinesterase; alpha-Glucosidases; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Molecular Docking Simulation; Molecular Structure; Pyridines; Saccharomyces cerevisiae; Structure-Activity Relationship; Sulfonamides | 2015 |
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amidohydrolases; Butyrylcholinesterase; Carbamates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2016 |
In silico studies, synthesis and pharmacological evaluation to explore multi-targeted approach for imidazole analogues as potential cholinesterase inhibitors with neuroprotective role for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Electrophorus; Female; Horses; Imidazoles; Male; Maze Learning; Memory Disorders; Mice; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship | 2018 |
Derivatives of montanine-type alkaloids and their implication for the treatment of Alzheimer's disease: Synthesis, biological activity and in silico study.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Isoquinolines; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2021 |
Design, synthesis, and biological evaluation of carbamate derivatives of N-salicyloyl tryptamine as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Drug Design; Humans; Male; Maze Learning; Molecular Docking Simulation; Neuroprotective Agents; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tryptamines | 2022 |
Computational insight into the anticholinesterase activities and electronic properties of physostigmine analogs.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Cluster Analysis; Humans; Ligands; Molecular Dynamics Simulation; Physostigmine; Principal Component Analysis; Protein Binding; Quantum Theory; Thermodynamics | 2019 |
Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Down Syndrome; Endosomes; Humans; Mice; Neurons; Phenotype; Phosphorylation; Physostigmine | 2021 |
Discovery of new acetylcholinesterase inhibitors for Alzheimer's disease: virtual screening and
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Electrophorus; Molecular Docking Simulation; Molecular Structure; Physostigmine; Structure-Activity Relationship | 2021 |
Seizure susceptibility in the APP/PS1 mouse model of Alzheimer's disease and relationship with amyloid β plaques.
Topics: Alzheimer Disease; Animals; Benzylamines; Cerebral Cortex; Disease Models, Animal; Disease Susceptibility; Electrocorticography; Female; Male; Mice, Inbred C57BL; Mice, Transgenic; Pentylenetetrazole; Physostigmine; Plaque, Amyloid; Seizures | 2017 |
(-)-Phenserine and the prevention of pre-programmed cell death and neuroinflammation in mild traumatic brain injury and Alzheimer's disease challenged mice.
Topics: Alzheimer Disease; Animals; Brain Concussion; Cell Death; Cerebral Cortex; Disease Models, Animal; Hippocampus; Mice; Mice, Transgenic; Neurons; Physostigmine | 2019 |
Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cell Proliferation; Disease Models, Animal; Doublecortin Protein; Female; Hippocampus; Interleukin-1beta; Male; Mice; Mice, Transgenic; Neuronal Plasticity; Neurons; Physostigmine; Plaque, Amyloid; Synapses; Tumor Necrosis Factor-alpha | 2013 |
Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease.
Topics: 5' Untranslated Regions; alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Aniline Compounds; Animals; Base Sequence; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; Down Syndrome; Humans; Iron; Iron Regulatory Protein 1; Mice; Mice, Transgenic; Molecular Sequence Data; Neurons; Physostigmine; Protein Binding; Protein Biosynthesis; Response Elements; RNA, Messenger; Sequence Homology, Nucleic Acid | 2013 |
Neural Stem Cell Transplant-Induced Effect on Neurogenesis and Cognition in Alzheimer Tg2576 Mice Is Inhibited by Concomitant Treatment with Amyloid-Lowering or Cholinergic α7 Nicotinic Receptor Drugs.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Carbamates; Cell Proliferation; Cognition; Doublecortin Protein; Female; Hippocampus; Humans; Male; Maze Learning; Memory; Mice; Nerve Regeneration; Neural Stem Cells; Neurogenesis; Nicotinic Agonists; Physostigmine; Quinuclidines; Stem Cell Transplantation | 2015 |
Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.
Topics: Alzheimer Disease; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Molecular Docking Simulation; Physostigmine | 2017 |
Muscarinic, Ca(++) antagonist and specific butyrylcholinesterase inhibitory activity of dried ginger extract might explain its use in dementia.
Topics: Acetylcholine; Alzheimer Disease; Animals; Atropine; Butyrylcholinesterase; Calcium; Calcium Channel Blockers; Catechols; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Fatty Alcohols; Gastric Fundus; In Vitro Techniques; Molecular Structure; Muscarinic Agonists; Parasympatholytics; Physostigmine; Plant Extracts; Rats; Rats, Sprague-Dawley; Rhizome; Verapamil; Zingiber officinale | 2008 |
The perils of Alzheimer's drug development.
Topics: Alzheimer Disease; Animals; Biomedical Research; Clinical Trials as Topic; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Evaluation; Drug Industry; Humans; Observer Variation; Physostigmine; Selection Bias | 2009 |
Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Ligands; Models, Molecular; Physostigmine; Quantitative Structure-Activity Relationship | 2009 |
Synthesis of (+)-phenserine using an interrupted Fischer indolization reaction.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Indoles; Molecular Structure; Physostigmine; Pyrrolidines; Stereoisomerism | 2012 |
Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances?
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Physostigmine; Research Design; Treatment Failure | 2013 |
Was phenserine a failure or were investigators mislead by methods?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Humans; MEDLINE; Physostigmine; Randomized Controlled Trials as Topic; Research Design; Treatment Failure | 2012 |
Editorial (hot topic:modulation of cholinergic system activity in neuronal and non-neuronal tissues: therapeutic implications).
Topics: Acetylcholine; Alzheimer Disease; Butyrylcholinesterase; Cholinergic Agents; Humans; Inflammation; MicroRNAs; Physostigmine | 2013 |
Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and cholinergi
Topics: alpha-Synuclein; Alzheimer Disease; Amyloid beta-Protein Precursor; Humans; Interleukin-1beta; Physostigmine; Plaque, Amyloid; Receptors, Muscarinic; Receptors, Nicotinic; Stereoisomerism | 2013 |
Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Inflammation Mediators; MAP Kinase Kinase 4; Molecular Docking Simulation; p38 Mitogen-Activated Protein Kinases; Physostigmine; tau Proteins; Tumor Necrosis Factor-alpha | 2013 |
Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doublecortin Protein; Drug Discovery; Gene Expression Regulation; Humans; Mice; Mice, Transgenic; Mutation; Neural Stem Cells; Neurons; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Physostigmine; Stereoisomerism | 2013 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Edrophonium; Humans; In Vitro Techniques; Phenylcarbamates; Physostigmine; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer's disease.
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Humans; Indans; Male; Mice; Physostigmine; Piperidines; Rats; Rats, Sprague-Dawley; Tacrine | 2004 |
An investigation of the effect of tacrine and physostigmine on spatial working memory deficits in the olfactory bulbectomised rat.
Topics: Alzheimer Disease; Animals; Arousal; Basal Nucleus of Meynert; Cholinergic Fibers; Cholinesterase Inhibitors; Defecation; Escape Reaction; Injections, Intraperitoneal; Maze Learning; Memory, Short-Term; Motor Activity; Olfactory Bulb; Orientation; Physostigmine; Rats; Rats, Sprague-Dawley; Social Environment; Tacrine | 2004 |
Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Behavior, Animal; Cholinesterase Inhibitors; Conditioning, Psychological; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Fear; Genetics, Behavioral; Heterozygote; Humans; Indans; Learning; Memory; Memory Disorders; Mice; Mice, Transgenic; Physostigmine; Piperidines; Plaque, Amyloid; Spatial Behavior | 2005 |
In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Topics: Acetylcholinesterase; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Carbon Radioisotopes; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Physostigmine; Piperidines; Positron-Emission Tomography; Reproducibility of Results; Synapses | 2006 |
Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Physostigmine; Protein Binding | 2006 |
Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Enzyme-Linked Immunosorbent Assay; Extracellular Space; Humans; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Neuroprotective Agents; Physostigmine; RNA, Messenger; Stereoisomerism; Structure-Activity Relationship | 2006 |
Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Physostigmine; Time Factors | 2006 |
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Cell Line, Tumor; Cerebral Cortex; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred C57BL; Physostigmine; RNA, Messenger; Stereoisomerism | 2007 |
Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Humans; Indoles; Molecular Structure; Neurons; Physostigmine; Pyrroles | 2007 |
Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine.
Topics: Alzheimer Disease; Amyloid; Animals; Cell Differentiation; Cells, Cultured; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Humans; Mice; Mice, Transgenic; Neuroglia; Neurons; Physostigmine; Stem Cell Transplantation; Stem Cells | 2007 |
Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Topics: Alzheimer Disease; Benzoxepins; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Physostigmine | 2008 |
Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis.
Topics: Alzheimer Disease; Binding, Competitive; Butyrylcholinesterase; Drug Evaluation, Preclinical; Enzyme Inhibitors; Furans; Humans; Kinetics; Molecular Structure; Physostigmine; Serum | 2008 |
Impaired muscarinic regulation of excitatory synaptic transmission in the APPswe/PS1dE9 mouse model of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Blotting, Western; Cholinesterase Inhibitors; Disease Models, Animal; Electric Stimulation; Electrophysiology; Excitatory Postsynaptic Potentials; Glutamic Acid; In Vitro Techniques; Mice; Mice, Transgenic; Muscarinic Antagonists; Nicotinic Antagonists; Patch-Clamp Techniques; Physostigmine; Presenilin-1; Receptors, Muscarinic; Receptors, Nicotinic; Synaptic Transmission | 2008 |
Oral physostigmine in Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Double-Blind Method; Drug Evaluation; Humans; Physostigmine | 1983 |
Oral physostigmine and lecithin improve memory in Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Humans; Phosphatidylcholines; Physostigmine | 1983 |
Acetylcholinesterase activity in CSF in schizophrenia, depression, Alzheimer's disease and normals.
Topics: Acetylcholinesterase; Adult; Aged; Alzheimer Disease; Cerebrospinal Fluid Proteins; Cholinesterase Inhibitors; Depressive Disorder; Dyskinesia, Drug-Induced; Humans; Middle Aged; Physostigmine; Schizophrenia | 1983 |
Long-term administration of oral physostigmine and lecithin improve memory in Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Humans; Memory Disorders; Phosphatidylcholines; Physostigmine | 1984 |
Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.
Topics: Alzheimer Disease; Female; Humans; Male; Middle Aged; Parasympathetic Nervous System; Physostigmine; Psychomotor Performance | 1984 |
Toward an effective treatment of Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Cognition; Dementia; Female; Humans; Male; Physostigmine | 1983 |
No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Clinical Trials as Topic; Dementia; Double-Blind Method; Female; Humans; Male; Memory; Middle Aged; Phosphatidylcholines; Physostigmine; Verbal Learning | 1983 |
Acute administration of individual optimal dose of physostigmine fails to improve mnesic performances in Alzheimers Presenile Dementia.
Topics: Alzheimer Disease; Cholinesterases; Dementia; Humans; Memory; Physostigmine | 1983 |
The dementia dilemma: help is out there.
Topics: Aged; Alzheimer Disease; Ambulatory Care Facilities; Benzyl Alcohols; Dementia; Drug Combinations; Health Services for the Aged; Humans; Naloxone; Physician's Role; Physostigmine; Washington | 1983 |
Cholinesterase inhibitors and opiate antagonists in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Dementia; Female; Humans; Male; Middle Aged; Naloxone; Physostigmine | 1983 |
Physostigmine in the treatment of memory disorders: a case report.
Topics: Alzheimer Disease; Amnesia; Dementia; Humans; Male; Middle Aged; Physostigmine | 1982 |
Research subject recruitment for gerontological studies of pharmacological agents.
Topics: Aged; Aging; Alzheimer Disease; Clinical Trials as Topic; Female; Humans; Male; Memory Disorders; Middle Aged; Physostigmine | 1982 |
Oral administration of chronic physostigmine does not improve cognitive or mnesic performances in Alzheimer's presenile dementia.
Topics: Alzheimer Disease; Arousal; Cognition; Dementia; Humans; Memory; Mental Recall; Middle Aged; Physostigmine; Psychological Tests | 1982 |
Physostigmine and its effect on six patients with dementia.
Topics: Aged; Alzheimer Disease; Dementia; Double-Blind Method; Female; Humans; Injections, Intravenous; Male; Memory; Middle Aged; Physostigmine | 1981 |
Neurochemical approaches to the treatment of senile dementia.
Topics: Acetylcholine; Aged; Alzheimer Disease; Animals; Choline; Choline O-Acetyltransferase; Dementia; Dyskinesia, Drug-Induced; Female; Humans; Learning; Male; Memory; Middle Aged; Phosphatidylcholines; Physostigmine; Rats; Receptors, Cholinergic | 1980 |
Observations on the physostigmine syndrome in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Physostigmine | 1991 |
Cholinomimetics increase glutamate outflow via an action on the corticostriatal pathway: implications for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Bridged Bicyclo Compounds, Heterocyclic; Cerebral Cortex; Cholinergic Agents; Corpus Striatum; Glutamic Acid; Male; Neural Pathways; Neurons; Oximes; Physostigmine; Rats; Rats, Sprague-Dawley | 1995 |
Anticholinesterasic drugs: tacrine but not physostigmine, accumulates in acidic compartments of the cells.
Topics: Acridine Orange; Alzheimer Disease; Animals; Biological Transport, Active; Cell Line; Humans; Hydrogen-Ion Concentration; In Vitro Techniques; Liver; Lysosomes; Male; Mice; Organelles; Physostigmine; Rats; Rats, Wistar; T-Lymphocytes; Tacrine | 1995 |
A novel acetylcholinesterase inhibitor, Ro 46-5934, which interacts with muscarinic M2 receptors.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Corpus Striatum; Extracellular Space; Humans; Indoles; Muscarinic Antagonists; Physostigmine; Rats; Receptors, Muscarinic; Scopolamine | 1994 |
Effects of cholinesterase inhibitors on learning and memory in rats: a brief review with special reference to THA.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain; Cholinesterase Inhibitors; Learning; Memory; Physostigmine; Rats; Tacrine | 1993 |
A peptide enhancement strategy in Alzheimer's disease: pilot study with TRH-physostigmine infusions.
Topics: Aged; Alzheimer Disease; Blood Pressure; Cognition Disorders; Drug Therapy, Combination; Female; Humans; Male; Neuropsychological Tests; Peptides; Physostigmine; Pilot Projects; Task Performance and Analysis; Thyrotropin-Releasing Hormone | 1993 |
Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma.
Topics: Administration, Oral; Aged; Alzheimer Disease; Arginine Vasopressin; Cholinesterase Inhibitors; Delayed-Action Preparations; Female; Humans; Male; Norepinephrine; Physostigmine; Water-Electrolyte Balance | 1995 |
Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging study.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dihydropyridines; Ethics, Medical; Humans; Nootropic Agents; Oximes; Physostigmine; Psychotropic Drugs; Pyridines; Tacrine; Thiadiazoles | 1995 |
Hypothalamic-pituitary-adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Aged; Alzheimer Disease; beta-Endorphin; Cholinergic Fibers; Cholinesterase Inhibitors; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Mental Status Schedule; Physostigmine; Pituitary-Adrenal System; Reference Values; Sex Factors | 1996 |
Pharmacodynamic monitoring of eptastigmine in capillary blood.
Topics: Acetylcholinesterase; Adult; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Male; Middle Aged; Physostigmine; Time Factors | 1996 |
[Neuroprotective therapy of Alzheimer's disease?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Neuroprotective Agents; Physostigmine; Piracetam; Tacrine | 1996 |
Physostigmine reversal of scopolamine-induced hypofrontality.
Topics: Acetylcholine; Adult; Alzheimer Disease; Amnesia; Blood-Brain Barrier; Cerebrovascular Circulation; Frontal Lobe; Hemodynamics; Humans; Male; Mental Recall; Muscarinic Antagonists; Neostigmine; Parasympathomimetics; Physostigmine; Radionuclide Imaging; Receptors, Muscarinic; Scopolamine; Xenon Radioisotopes | 1997 |
Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Isoflurophate; Male; Muscarinic Antagonists; Physostigmine; Prosencephalon; Rats; Rats, Sprague-Dawley; Scopolamine | 1997 |
Physostigmine and Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Physostigmine | 1997 |
Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Basal Ganglia; Brain; Calcium Channel Blockers; Cholinesterase Inhibitors; Male; Physostigmine; Psychomotor Performance; Rats; Rats, Wistar; Verapamil | 1997 |
A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Acridines; Alzheimer Disease; Animals; Benzylamines; Brain; Cholinesterase Inhibitors; Drug Design; Electrophorus; Erythrocytes; Humans; Mathematics; Mice; Molecular Structure; Physostigmine; Rats; Structure-Activity Relationship | 1997 |
Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Kinetics; Physostigmine; Substrate Specificity | 1997 |
Donepezil medicated memory improvement in traumatic brain injury during post acute rehabilitation.
Topics: Adult; Alzheimer Disease; Brain Injuries; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Donepezil; Female; Head Injuries, Closed; Humans; Indans; Male; Memory; Memory Disorders; Mental Recall; Middle Aged; Physical Therapy Modalities; Physostigmine; Piperidines; Temporal Lobe | 1998 |
Cardiac autonomic dysfunction in patients with Alzheimer disease: possible pathogenetic mechanisms.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Autonomic Nervous System; Autonomic Nervous System Diseases; Cholinesterase Inhibitors; Electrocardiography; Erythrocytes; Female; Fourier Analysis; Heart; Heart Rate; Humans; Male; Middle Aged; Physostigmine; Signal Processing, Computer-Assisted | 1998 |
[Drugs for Alzheimer disease: what will the minister decide].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Drug Approval; Female; Health Policy; Humans; Male; Middle Aged; Netherlands; Neurobehavioral Manifestations; Physostigmine; Religion and Medicine | 1998 |
Bis(7)-tacrine, a novel dimeric AChE inhibitor, is a potent GABA(A) receptor antagonist.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Electric Stimulation; Electrophysiology; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Hippocampus; Membrane Potentials; Mice; Neurons; Patch-Clamp Techniques; Physostigmine; Radioligand Assay; Rats; Receptors, Muscarinic; Tacrine | 1999 |
Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Erythrocytes; Humans; Physostigmine; Structure-Activity Relationship | 1999 |
Acetylcholine affects the spatial scale of attention: evidence from Alzheimer's disease.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Arousal; Attention; Case-Control Studies; Cholinergic Agents; Cholinesterase Inhibitors; Cues; Female; Humans; Male; Middle Aged; Models, Neurological; Muscarinic Antagonists; Pattern Recognition, Visual; Physostigmine; Scopolamine; Space Perception | 2000 |
Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine.
Topics: Acetylcholinesterase; Alzheimer Disease; Binding, Competitive; Cholinesterase Inhibitors; Humans; Kinetics; Physostigmine | 2000 |
Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Middle Aged; Physostigmine; Piperidines; Tomography, Emission-Computed | 2000 |
Plasma catecholamine and cardiovascular responses to physostigmine in Alzheimer's disease and aging.
Topics: Adrenal Medulla; Adult; Aged; Alzheimer Disease; Arousal; Blood Pressure; Brain; Epinephrine; Female; Humans; Male; Norepinephrine; Physostigmine; Reference Values; Sympathetic Nervous System | 2001 |
Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.
Topics: Alkaloids; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Avoidance Learning; Cholinesterase Inhibitors; Male; Mice; Mice, Inbred ICR; Muscarinic Antagonists; Peptide Fragments; Physostigmine; Scopolamine | 2001 |
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Animals; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; In Vitro Techniques; Indans; Inhibitory Concentration 50; Male; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rivastigmine; Tacrine; Time Factors | 2000 |
The experimental Alzheimer drug phenserine: preclinical pharmacokinetics and pharmacodynamics.
Topics: Administration, Oral; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Half-Life; Infusions, Intravenous; Male; Physostigmine; Rats; Rats, Inbred F344; Tacrine | 2000 |
Drug combination may improve memory.
Topics: Alzheimer Disease; Dementia; Drug Therapy, Combination; Humans; Phosphatidylcholines; Physostigmine | 1979 |
Possible biochemical basis of memory disorder in Alzheimer's disease.
Topics: Adult; Alzheimer Disease; Dementia; Humans; Male; Memory; Memory Disorders; Physostigmine | 1979 |
[Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on synaptosomal uptake of neuromediators].
Topics: Alzheimer Disease; Aminoquinolines; Animals; Cholinesterase Inhibitors; Dopamine; Epinephrine; gamma-Aminobutyric Acid; Neurotransmitter Agents; Norepinephrine; Physostigmine; Piracetam; Psychotropic Drugs; Rats; Serotonin; Synaptosomes; Tacrine | 1992 |
Differential inhibition of acetylcholinesterase molecular forms in normal and Alzheimer disease brain.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Centrifugation, Density Gradient; Cholinesterase Inhibitors; Edrophonium; Female; Humans; Male; Physostigmine; Protein Conformation; Sucrose | 1992 |
PET imaging in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cognition Disorders; Female; Humans; Male; Middle Aged; Physostigmine; Psychiatric Status Rating Scales; Regional Blood Flow; Tomography, Emission-Computed | 1992 |
Kinetics of cholinesterase inhibition by eptastigmine in man.
Topics: Adult; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Kinetics; Male; Physostigmine | 1991 |
Reciprocal changes in psychosis and mood after physostigmine in a patient with Alzheimer's disease.
Topics: Alzheimer Disease; Depressive Disorder; Female; Humans; Middle Aged; Physostigmine; Psychiatric Status Rating Scales | 1991 |
[Study of anti-amnesic activity of amiridin in a model of amnesic syndrome].
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Amnesia; Animals; Cerebral Cortex; Cholinesterase Inhibitors; In Vitro Techniques; Lipids; Male; Physostigmine; Piracetam; Psychotropic Drugs; Rats; Scopolamine; Synaptosomes; Syndrome; Tacrine | 1991 |
Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats.
Topics: Alzheimer Disease; Animals; Avoidance Learning; Benzylamines; Cholinergic Agents; Cholinergic Fibers; Clonidine; Disease Models, Animal; Male; Memory; Organic Chemicals; Oxotremorine; Parasympathomimetics; Physostigmine; Rats; Rats, Inbred Strains; Substantia Innominata | 1991 |
[Cholinesterase inhibitor].
Topics: Acetylcholine; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Humans; Learning Disabilities; Memory; Neurons; Physostigmine; Scopolamine; Tacrine | 1991 |
Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Cerebrovascular Circulation; Drug Evaluation; Female; Glycopyrrolate; Humans; Infusions, Intravenous; Male; Middle Aged; Organotechnetium Compounds; Oximes; Parasympathetic Nervous System; Parietal Lobe; Physostigmine; Technetium Tc 99m Exametazime; Temporal Lobe; Tomography, Emission-Computed, Single-Photon | 1990 |
Regional cerebral blood flow in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cerebrovascular Circulation; Humans; Middle Aged; Physostigmine | 1990 |
Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Avoidance Learning; Cerebral Cortex; Choline O-Acetyltransferase; Corticotropin-Releasing Hormone; Cysteamine; Disease Models, Animal; Dopamine; Hydroxydopamines; Ibotenic Acid; Male; Norepinephrine; Oxidopamine; Physostigmine; Rats; Rats, Inbred Strains; Reference Values; Serotonin; Somatostatin | 1990 |
Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Dominance, Cerebral; Humans; Neuropsychological Tests; Organotechnetium Compounds; Oximes; Physostigmine; Regional Blood Flow; Technetium Tc 99m Exametazime; Tomography, Emission-Computed, Single-Photon | 1991 |
Selective changes in sensitivity to cholinergic agonists and receptor changes elicited by continuous physostigmine infusion.
Topics: Acetylcholinesterase; Alzheimer Disease; Analysis of Variance; Animals; Body Temperature; Brain; Dose-Response Relationship, Drug; Female; Mice; Mice, Inbred C57BL; Nicotine; Parasympatholytics; Parasympathomimetics; Physostigmine; Receptors, Nicotinic | 1990 |
The effect of long-term physostigmine administration in Alzheimer's disease.
Topics: Alzheimer Disease; Female; Follow-Up Studies; Humans; Intelligence Tests; Male; Middle Aged; Neuropsychological Tests; Physostigmine; Statistics as Topic; Time Factors | 1990 |
9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.
Topics: Alzheimer Disease; Aminoacridines; Animals; Atropine; Cerebral Cortex; Cholinesterase Inhibitors; Corpus Striatum; Electrophysiology; In Vitro Techniques; Ion Channels; Lymnaea; Male; Oxotremorine; Physostigmine; Rats; Rats, Inbred Strains; Tacrine | 1987 |
Neuroendocrine responses to physostigmine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Arginine Vasopressin; beta-Endorphin; Blood Pressure; Brain; Epinephrine; Humans; Infusions, Intravenous; Male; Parasympathetic Nervous System; Physostigmine | 1989 |
Altered P300 topography due to functional and structural disturbances in the limbic system in dementia and psychoses and to pharmacological conditions.
Topics: Adult; Aged; Alzheimer Disease; Arousal; Attention; Biperiden; Electroencephalography; Evoked Potentials, Auditory; Humans; Limbic System; Physostigmine; Piperidines; Reaction Time; Schizophrenia; Signal Processing, Computer-Assisted | 1989 |
Continuous physostigmine infusion in rats with excitotoxic lesions of the nucleus basalis magnocellularis: effects on performance in the water maze task and cortical cholinergic markers.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Basal Ganglia; Cerebral Cortex; Choline O-Acetyltransferase; Infusions, Intravenous; Learning; Male; Memory; Parasympathetic Nervous System; Physostigmine; Rats; Rats, Inbred F344; Receptors, Muscarinic; Substantia Innominata | 1989 |
Animal models of Alzheimer's disease: behavior, pharmacology, transplants.
Topics: 4-Aminopyridine; Alzheimer Disease; Aminopyridines; Animals; Behavior, Animal; Brain; Disease Models, Animal; Fetus; Growth Substances; Humans; Nerve Growth Factors; Nerve Tissue; Nerve Tissue Proteins; Nervous System Diseases; Norepinephrine; Parasympathetic Nervous System; Physostigmine; Somatostatin | 1986 |
Brain diseases in the elderly: clinical aspects and management.
Topics: Aged; Alzheimer Disease; Cerebral Cortex; Corticotropin-Releasing Hormone; Diagnosis, Differential; Humans; Neurofibrils; Neurotransmitter Agents; Phospholipids; Physostigmine; Risk; Tomography, X-Ray Computed | 1987 |
Plasma physostigmine concentrations after controlled-release oral administration.
Topics: Administration, Oral; Alzheimer Disease; Delayed-Action Preparations; Humans; Male; Physostigmine | 1989 |
Determination of physostigmine in plasma and cerebrospinal fluid by liquid chromatography with electrochemical detection.
Topics: Alzheimer Disease; Chromatography, High Pressure Liquid; Electrochemistry; Humans; Infusions, Intravenous; Physostigmine | 1989 |
Differential responsivity of verbal and visual recognition memory to physostigmine and ACTH.
Topics: Adrenocorticotropic Hormone; Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Female; Form Perception; Humans; Memory; Mental Recall; Neuropsychological Tests; Pattern Recognition, Visual; Physostigmine; Retention, Psychology; Verbal Learning | 1986 |
[Alzheimer's disease. Biological and pharmacotherapeutic aspects].
Topics: Alzheimer Disease; Brain; Humans; Parasympathomimetics; Physostigmine; Synaptic Transmission | 1986 |
Effects of physostigmine on memory test performance in normal volunteers.
Topics: Adolescent; Adult; Alzheimer Disease; Humans; Memory; Physostigmine | 1986 |
Effects of intracerebroventricular injection of AF64A on learning behaviors in rats.
Topics: Alzheimer Disease; Amnesia; Animals; Avoidance Learning; Aziridines; Azirines; Choline; Choline O-Acetyltransferase; Disease Models, Animal; Hippocampus; Injections, Intraventricular; Learning; Male; Physostigmine; Rats; Rats, Inbred Strains | 1988 |
New analogs of physostigmine: alternative drugs for Alzheimer's disease?
Topics: Alzheimer Disease; Animals; Avoidance Learning; Brain; Chemical Phenomena; Chemistry; Cholinesterase Inhibitors; Cholinesterase Reactivators; Male; Mice; Motor Activity; Physostigmine; Rats; Rats, Inbred Strains; Scopolamine; Structure-Activity Relationship | 1988 |
Auditory long latency event-related potentials in Alzheimer's disease and multi-infarct dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Auditory Perception; Brain; Dementia, Multi-Infarct; Evoked Potentials, Auditory; Female; Humans; Male; Middle Aged; Physostigmine; Pitch Discrimination; Reaction Time; Wechsler Scales | 1988 |
Pharmacological modulation of cortisol secretion and dexamethasone suppression in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clonidine; Depressive Disorder; Dexamethasone; Female; Humans; Hydrocortisone; Male; Physostigmine | 1988 |
Physostigmine, auditory P300, and Alzheimer's disease.
Topics: Alzheimer Disease; Evoked Potentials, Visual; Humans; Memory; Physostigmine | 1988 |
Anatomy of cholinesterase inhibition in Alzheimer's disease: effect of physostigmine and tetrahydroaminoacridine on plaques and tangles.
Topics: Acetylcholinesterase; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Aminoacridines; Cholinesterase Inhibitors; Female; Histocytochemistry; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Neurofibrils; Physostigmine; Tacrine | 1987 |
Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?
Topics: Acetylcholine; Aged; Alzheimer Disease; Aminoacridines; Dementia; Female; Frontal Lobe; Humans; In Vitro Techniques; Male; Physostigmine; Receptors, Nicotinic; Tacrine | 1987 |
The effects of physostigmine on memory and auditory P300 in Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Evoked Potentials, Auditory; Female; Humans; Infusions, Parenteral; Male; Memory; Mental Recall; Middle Aged; Pattern Recognition, Visual; Physostigmine; Reaction Time | 1986 |
Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Eels; In Vitro Techniques; Kinetics; Mathematics; Physostigmine | 1986 |
Hypertension associated with oral administration of physostigmine in a patient with Alzheimer's disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Female; Humans; Hypertension; Physostigmine | 1986 |
Physostigmine in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Humans; Physostigmine | 1986 |
Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease.
Topics: Administration, Oral; Alzheimer Disease; Dose-Response Relationship, Drug; Humans; Memory; Phosphatidylcholines; Physostigmine; Time Factors | 1986 |
Physostigmine restores 3H-acetylcholine efflux from Alzheimer brain slices to normal level.
Topics: Acetylcholine; Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Female; Humans; In Vitro Techniques; Male; Physostigmine | 1986 |
Physostigmine-induced myoclonus in Alzheimer's disease.
Topics: Acetylcholine; Aged; Alzheimer Disease; Brain; Choline O-Acetyltransferase; Female; Humans; Male; Middle Aged; Myoclonus; Physostigmine | 1987 |
Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels.
Topics: Adult; Alzheimer Disease; Arrhythmias, Cardiac; Blood Pressure; Depressive Disorder; Epinephrine; Humans; Hypertension; Middle Aged; N-Methylscopolamine; Parasympatholytics; Physostigmine; Pulse; Scopolamine Derivatives | 1985 |
Pharmacological alleviation of cholinergic lesion induced memory deficits in rats.
Topics: Alzheimer Disease; Animals; Basal Ganglia; Cholinergic Fibers; Humans; Male; Memory Disorders; Motor Activity; Physostigmine; Rats; Rats, Inbred Strains; Substantia Innominata; Time Factors | 1985 |
Dose-related physostigmine-induced ventricular arrhythmia: case report.
Topics: Aged; Alzheimer Disease; Arrhythmias, Cardiac; Double-Blind Method; Humans; Male; Memory Disorders; Physostigmine; Placebos | 1985 |
Recognition memory in Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Cholinergic Fibers; Female; Humans; Male; Memory; Physostigmine; Verbal Behavior | 1985 |